NanJing Pharmaceutical Company Limited: history, ownership, mission, how it works & makes money

From its origins in 1951 to its Shanghai listing under ticker 600713 in 1996, NanJing Pharmaceutical Company Limited has evolved into a major distributor in China's healthcare supply chain-reporting as of September 30, 2025 a total revenue of 54.43 billion yuan and net income of 530.72 million yuan, operating roughly 1,308,929,289 shares after convertible bond conversion and raising short-term liquidity like the 500 million yuan ultra-short-term financing note issued on June 12, 2025; with market capitalizations reported at about 6.57-6.82 billion yuan across October-December 2025, a P/E in the low teens, an enterprise value near 17.84 billion yuan, insider and institutional stakes of 0.17% and 1.56% respectively, the company blends wholesale, retail, e‑commerce, logistics and medical-device/rental revenues while investing in IT and supply‑chain reach-read on to unpack its history, ownership, mission, operating model and how these figures translate into sustainable cash flow and market positioning

NanJing Pharmaceutical Company Limited (600713.SS): Intro

• Founded: 1951 - origins as a municipal pharmaceutical distributor in Nanjing.
• Reorganized as joint-stock enterprise: 1994.
• Shanghai Stock Exchange listing: July 1, 1996 (Ticker: 600713).
• Name change: December 2025 - renamed Nanjing Pharmaceutical Group Company Limited to reflect expanded scope.
• Capital markets activity: June 12, 2025 - issued a fifth ultra-short-term financing note in 2025, raising ¥500 million.
• Share capital: as of September 30, 2025 - 1,308,929,289 total shares outstanding (post-conversion of convertible bonds).

• Ownership mix: a combination of state-related holdings, institutional investors, and public retail shareholders following listed status and bond conversions.
• Governance: board of directors and supervisory board aligned with Chinese listed-company practices; periodic disclosure of major shareholders in annual reports.

• Pharmaceutical distribution: procurement from manufacturers, warehousing, province-level distribution to hospitals, clinics and pharmacies; revenue driven by gross margin on distributed products and logistics fees.
• Retail pharmacy network: brick-and-mortar and community pharmacy sales, OTC and prescription dispensing, loyalty programs and last-mile fulfillment.
• Logistics & cold-chain: third-party logistics and temperature-controlled distribution services provided to drugmakers and distributors.
• Value-added services: supply-chain financing, inventory management, and basic contract manufacturing or packaging support for select partners.

• Product distribution margins: primary revenue source - margins vary by therapeutic category, manufacturer pricing and scale.
• Retail sales: higher-margin OTC and consumer healthcare products plus pharmacy services.
• Logistics revenue: contracts with manufacturers and wholesalers for warehousing and distribution fees.
• Financial operations: short-term debt issuance (e.g., ultra-short-term financing notes) to optimize working capital and interest spread management.

• Convertible bond conversions: increased share base to 1,308,929,289 shares as of 2025-09-30.
• Short-term funding: multiple ultra-short-term financing notes in 2025 - the fifth issue raised ¥500 million on Jun 12, 2025 - aimed at working capital and bank-loan repayment.
• Balance-sheet implications: increased liquidity flexibility but dilution effects from convertible conversions reflected in EPS and per-share metrics.

• Expand upstream and downstream integration across distribution, retail and logistics to capture more margin and enhance resilience to pricing pressure.
• Enhance digital ordering, inventory and last-mile fulfillment to reduce working-capital intensity and improve service levels to institutional clients.
• Pursue selective M&A and partnerships consistent with the corporate name change to Nanjing Pharmaceutical Group Company Limited (Dec 2025) and broader group ambitions.

NanJing Pharmaceutical Company Limited (600713.SS): History

• Founded: Evolved from earlier state-owned/local enterprises (regional manufacturing origins).
• Core businesses developed: APIs, sterile injectables, tablets/capsules, and specialty formulations.
• Strategic shifts: Increased GMP-compliant facilities and R&D collaborations in recent years.

• Insiders: 0.17% - limited internal equity alignment.
• Institutional investors: 1.56% - modest institutional concentration.
• Public float: Majority of shares, supporting liquidity on SSE (600713).

• Manufacturing: Revenue from production and sale of APIs and finished pharmaceuticals to hospitals, distributors, and wholesalers.
• Product mix: Higher-margin specialty formulations and sterile injectables complement volume-driven generic APIs.
• R&D and licensing: Incremental income from proprietary formulations, contract manufacturing, and technical transfer agreements.
• Export and domestic channels: Sales split between domestic hospital procurement and selective export markets, leveraging regulatory certifications to access new buyers.

NANJING PHARMACEUTICAL COMPANY LIMITED (600713.SS): Ownership Structure

• Mission: Ensure efficient distribution of pharmaceutical products and bridge accessibility gaps in China's healthcare system.
• Values: Supply-chain integrity, service quality, IT-driven optimization, corporate governance and ethical practice.
• Operational focus: Warehousing, cold-chain logistics, inventory management, regional distribution hubs and B2B/B2C pharmacy services.

• Distribution margins: Purchases from manufacturers and sale to hospitals/pharmacies-primary revenue source via gross margins on product turnover.
• Logistics & value-added services: Cold-chain logistics, repackaging, labeling, and clinical supply services command premium fees.
• Inventory financing & consignment models: Short-term financing and consignment agreements help optimize working capital and fee income.
• IT-driven efficiency: Investment in ERP/WMS and e-ordering platforms reduces stockouts and shrinkage, improving turnover and margin capture.

• Regional distribution centers across Jiangsu and neighboring provinces, supporting same/next-day delivery to institutional clients.
• Cold-chain capacity for temperature-sensitive biologics and vaccines, expanding as demand for specialty medicines grows.
• Integrated B2B ordering portals and API links to major hospital procurement systems to accelerate order-to-delivery cycles.

NanJing Pharmaceutical Company Limited (600713.SS): Mission and Values

• Distribution network: The company partners with numerous domestic and international pharmaceutical manufacturers to source branded and generic medicines, medical devices, and healthcare consumables.
• Wholesale operations: Supplies large healthcare institutions-public hospitals, private clinics-and independent pharmacies through regional distribution centers and account management teams.
• Retail pharmacy chain: Operates a network of retail pharmacies in key cities, providing over-the-counter (OTC) products, prescription fulfillment, and basic clinical services.
• E-commerce and digital channels: Maintains an e-commerce platform and mobile app to sell medicines and health products directly to consumers and to support hospital procurement and B2B customers.
• Logistics & distribution assets: Owns and operates a fleet of refrigerated and non-refrigerated vehicles, along with multiple regional warehouses to ensure cold-chain integrity and timely deliveries across provinces.
• IT and systems: Invests in ERP, warehouse management systems (WMS), and data analytics to optimize inventory turns, reduce stockouts, and improve order fulfillment accuracy.
• Regulatory compliance: Adheres to China's Good Supply Practice (GSP) and other regulatory standards, implementing quality control and traceability systems for distributed products.

• Wholesale distribution: Bulk sales of pharmaceuticals and medical devices to hospitals, clinics, and pharmacies-typically the largest revenue contributor.
• Retail pharmacy sales: Margin on OTC products and prescription dispensing through company-owned retail outlets.
• E-commerce and direct-to-consumer: Online sales via company platforms and third-party marketplaces; subscription and promotion programs increase recurring sales.
• Logistics & value-added services: Fees from warehousing, cold-chain logistics, and supply-chain management services provided to manufacturers and institutional clients.
• Private label and procurement services: Sourcing and selling lower-cost generics or private-label products to improve margins.

• Information technology: ERP, WMS, CRM and analytics to reduce inventory days, accelerate order fulfillment, and enable demand forecasting.
• Cold-chain infrastructure: Temperature-controlled warehouses and vehicles to handle vaccines and biologics-segment showing fast growth in demand.
• Compliance and quality systems: Batch-level traceability, supplier audits, and standardized SOPs to meet GSP and other regulatory requirements.
• Human capital: Training for pharmacists, logistics staff, and salesforce to improve service levels and regulatory adherence.

• Supplier qualification and periodic audits of manufacturing partners.
• GSP-compliant storage, handling, and documentation for all pharmaceutical batches.
• Cold-chain monitoring with temperature logs and alarms for biologics and vaccines.
• Pharmacist-led prescription verification and pharmacovigilance reporting systems.

• Expand e-commerce penetration and omnichannel integration to capture rising online demand for medicines and health products.
• Deepen partnerships with domestic and international manufacturers to secure stable supply and preferential pricing.
• Invest in cold-chain and specialty distribution to serve high-margin biologics and vaccine segments.
• Optimize inventory through digital forecasting to reduce working capital and improve cash conversion cycles.

NanJing Pharmaceutical Company Limited (600713.SS): How It Works

• Core wholesale distribution of prescription drugs and over‑the‑counter (OTC) medications to hospitals, clinics and pharmacies.
• Retail pharmacy operations (bricks‑and‑mortar) selling prescription and OTC products, health supplements and consumer healthcare items.
• E‑commerce platform enabling direct‑to‑consumer sales of pharmaceuticals, supplements and medical devices.
• Third‑party logistics and transportation services for pharmaceutical manufacturers and distributors.
• Rental and sale of medical equipment and third‑class medical devices to healthcare institutions and end users.
• Sale of food products and other healthcare‑related goods to diversify revenue streams.

• Total revenue: RMB 35.2 billion (latest annual report).
• Gross profit margin: ~9%-11% (driven by wholesale volumes and retail mix).
• Net profit margin: ~3%-5% (after distribution costs, SG&A and logistics investment).
• Capital expenditure focus: expansion of cold‑chain logistics, retail store upgrades and IT for e‑commerce fulfillment.

• Large purchasing volumes secure supplier rebates, price differentials and working capital advantages that lower COGS.
• Retail and e‑commerce sales increase direct margin capture and provide higher margin cross‑sell opportunities (supplements, devices).
• Logistics contracts yield recurring revenue and better utilization of warehousing/cold‑chain assets, improving fixed‑cost absorption.
• Medical equipment rentals produce recurring fee income and after‑sales service revenue streams.
• Third‑class medical device sales and food/health product lines diversify gross margin sources and reduce reliance on low‑margin bulk drug distribution.

• Scale retail footprint and improve same‑store sales via loyalty programs and category expansion (supplements, devices).
• Expand e‑commerce assortment, third‑party marketplace partnerships and direct distribution to increase online share.
• Invest in cold‑chain and value‑added logistics to win manufacturer contracts and raise logistics revenue.
• Develop higher‑margin service lines (equipment rental, maintenance, chronic disease management programs).
• Broaden product portfolio to include third‑class medical devices and nutritional/food products to diversify margins.

NanJing Pharmaceutical Company Limited (600713.SS): How It Makes Money

• Wholesale distribution of prescription and OTC drugs to hospitals, clinics and pharmacies
• Retail pharmacy operations and front-end healthcare services
• Logistics, cold-chain and procurement services for manufacturers and medical institutions
• E‑commerce platform sales and digital healthcare services (growing focus)
• Value‑added services: inventory financing, data and IT solutions for clients